Clinical impacts of the concomitant use of L-asparaginase and total parenteral nutrition containing L-aspartic acid in patients with acute lymphoblastic leukemia.

Front Nutr · 2023 · PMC10106764 · PMID 37077904

Europe PMC DOI

hedged sentence

0.8500

closest p · 17.0× alpha

0.8500

boldest claim

The sentences

did not reach statistical significancep = 0.85not close (p > 0.1)

1 year after the start of the induction therapy, the concomitant use of ASNase and Asp-TPN led to an increase in the risk of early relapse (OR 1.24; 95% CI 0.50–3.12), and yet the OR did not reach statistical significance ( p = 0.85, Figure 4 ). 3.2.2.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.